Xeris Biopharma Holdings (XERS) Other Non-Current Assets (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Other Non-Current Assets came in at $5.1 million in Q1 2026, little changed YoY from $5.1 million in Q1 2025, and down 1.88% on a QoQ basis from $5.2 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Other Non-Current Assets data on file, last reported at $5.1 million in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.47% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (changed 0.47% YoY) and the FY2025 annual result came in at $5.2 million, down 3.46% from the prior year.
- Other Non-Current Assets slipped to $5.1 million in Q1 2026, from $5.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.5 million in Q2 2024 to a low of $2.2 million in Q3 2022.
- A 5-year average of $4.5 million and a median of $4.8 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 928.44% — and 2025, when it retreated 7.86%.
- Tracing XERS's Other Non-Current Assets over 5 years: stood at $4.7 million in 2022, then dropped by 4.02% to $4.5 million in 2023, then rose by 19.1% to $5.4 million in 2024, then retreated by 3.46% to $5.2 million in 2025, then fell by 1.88% to $5.1 million in 2026.
- The last three Other Non-Current Assets figures came in at $5.1 million (Q1 2026), $5.2 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 5.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.03 Mn |
| Mar 31, 2026 | 5.12 Mn |
| Dec 31, 2025 | 5.22 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 5.41 Mn |
| Sep 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | 5.49 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 4.54 Mn |
| Sep 30, 2023 | 4.81 Mn |
| Jun 30, 2023 | 4.81 Mn |
| Mar 31, 2023 | 4.73 Mn |
| Dec 31, 2022 | 4.73 Mn |
| Sep 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 2.35 Mn |
| Mar 31, 2022 | 2.18 Mn |
| Dec 31, 2021 | 829,000.00 |
| Sep 30, 2021 | 211,000.00 |